Cargando…

Applying artificial intelligence for cancer immunotherapy

Artificial intelligence (AI) is a general term that refers to the use of a machine to imitate intelligent behavior for performing complex tasks with minimal human intervention, such as machine learning; this technology is revolutionizing and reshaping medicine. AI has considerable potential to perfe...

Descripción completa

Detalles Bibliográficos
Autores principales: Xu, Zhijie, Wang, Xiang, Zeng, Shuangshuang, Ren, Xinxin, Yan, Yuanliang, Gong, Zhicheng
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8642413/
https://www.ncbi.nlm.nih.gov/pubmed/34900525
http://dx.doi.org/10.1016/j.apsb.2021.02.007
_version_ 1784609678549843968
author Xu, Zhijie
Wang, Xiang
Zeng, Shuangshuang
Ren, Xinxin
Yan, Yuanliang
Gong, Zhicheng
author_facet Xu, Zhijie
Wang, Xiang
Zeng, Shuangshuang
Ren, Xinxin
Yan, Yuanliang
Gong, Zhicheng
author_sort Xu, Zhijie
collection PubMed
description Artificial intelligence (AI) is a general term that refers to the use of a machine to imitate intelligent behavior for performing complex tasks with minimal human intervention, such as machine learning; this technology is revolutionizing and reshaping medicine. AI has considerable potential to perfect health-care systems in areas such as diagnostics, risk analysis, health information administration, lifestyle supervision, and virtual health assistance. In terms of immunotherapy, AI has been applied to the prediction of immunotherapy responses based on immune signatures, medical imaging and histological analysis. These features could also be highly useful in the management of cancer immunotherapy given their ever-increasing performance in improving diagnostic accuracy, optimizing treatment planning, predicting outcomes of care and reducing human resource costs. In this review, we present the details of AI and the current progression and state of the art in employing AI for cancer immunotherapy. Furthermore, we discuss the challenges, opportunities and corresponding strategies in applying the technology for widespread clinical deployment. Finally, we summarize the impact of AI on cancer immunotherapy and provide our perspectives about underlying applications of AI in the future.
format Online
Article
Text
id pubmed-8642413
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Elsevier
record_format MEDLINE/PubMed
spelling pubmed-86424132021-12-09 Applying artificial intelligence for cancer immunotherapy Xu, Zhijie Wang, Xiang Zeng, Shuangshuang Ren, Xinxin Yan, Yuanliang Gong, Zhicheng Acta Pharm Sin B Review Artificial intelligence (AI) is a general term that refers to the use of a machine to imitate intelligent behavior for performing complex tasks with minimal human intervention, such as machine learning; this technology is revolutionizing and reshaping medicine. AI has considerable potential to perfect health-care systems in areas such as diagnostics, risk analysis, health information administration, lifestyle supervision, and virtual health assistance. In terms of immunotherapy, AI has been applied to the prediction of immunotherapy responses based on immune signatures, medical imaging and histological analysis. These features could also be highly useful in the management of cancer immunotherapy given their ever-increasing performance in improving diagnostic accuracy, optimizing treatment planning, predicting outcomes of care and reducing human resource costs. In this review, we present the details of AI and the current progression and state of the art in employing AI for cancer immunotherapy. Furthermore, we discuss the challenges, opportunities and corresponding strategies in applying the technology for widespread clinical deployment. Finally, we summarize the impact of AI on cancer immunotherapy and provide our perspectives about underlying applications of AI in the future. Elsevier 2021-11 2021-02-11 /pmc/articles/PMC8642413/ /pubmed/34900525 http://dx.doi.org/10.1016/j.apsb.2021.02.007 Text en © 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review
Xu, Zhijie
Wang, Xiang
Zeng, Shuangshuang
Ren, Xinxin
Yan, Yuanliang
Gong, Zhicheng
Applying artificial intelligence for cancer immunotherapy
title Applying artificial intelligence for cancer immunotherapy
title_full Applying artificial intelligence for cancer immunotherapy
title_fullStr Applying artificial intelligence for cancer immunotherapy
title_full_unstemmed Applying artificial intelligence for cancer immunotherapy
title_short Applying artificial intelligence for cancer immunotherapy
title_sort applying artificial intelligence for cancer immunotherapy
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8642413/
https://www.ncbi.nlm.nih.gov/pubmed/34900525
http://dx.doi.org/10.1016/j.apsb.2021.02.007
work_keys_str_mv AT xuzhijie applyingartificialintelligenceforcancerimmunotherapy
AT wangxiang applyingartificialintelligenceforcancerimmunotherapy
AT zengshuangshuang applyingartificialintelligenceforcancerimmunotherapy
AT renxinxin applyingartificialintelligenceforcancerimmunotherapy
AT yanyuanliang applyingartificialintelligenceforcancerimmunotherapy
AT gongzhicheng applyingartificialintelligenceforcancerimmunotherapy